Sign Up to like & get
recommendations!
1
Published in 2019 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-019-04385-6
Abstract: PurposeProstate-specific membrane antigen (PSMA) PET/CT is increasingly used in patients with biochemically recurrent prostate cancer (BCR), mostly using gallium-68 (168Ga)-labelled radiotracers. Alternatively, fluorine-18 (18F)-labelled PSMA tracers are available, such as 18F-DCFPyL, which offer enhanced image…
read more here.
Keywords:
cancer;
18f dcfpyl;
dcfpyl pet;
detection ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
1
Published in 2020 at "Advances in Radiation Oncology"
DOI: 10.1016/j.adro.2020.08.014
Abstract: Purpose Our purpose was to study the effect of 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) positron emission tomography (PET)-computed tomography (CT) on staging/treatment recommendations of previously untreated prostate cancer. We report here results of a prospective single center…
read more here.
Keywords:
pet;
18f dcfpyl;
treatment;
treatment recommendations ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2019 at "Clinical Nuclear Medicine"
DOI: 10.1097/rlu.0000000000002428
Abstract: A 69-year-old man with biochemical recurrence after radical prostatectomy underwent 6 months of androgen deprivation therapy. Upon discontinuation of androgen deprivation therapy, serum prostate-specific antigen rose again to 0.69 ng/mL, and F-DCFPyL PET/CT was performed…
read more here.
Keywords:
potential pitfall;
dcfpyl pet;
hemangioma potential;
splenic hemangioma ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
2
Published in 2023 at "Clinical nuclear medicine"
DOI: 10.1097/rlu.0000000000004600
Abstract: ABSTRACT A 64-year-old man with recently diagnosed prostate adenocarcinoma and Gleason score 4 + 3 = 7 with a mildly elevated prostate-specific antigen of 5.17 μg/L was referred for 18F-DCFPyL PET/CT for primary staging. The…
read more here.
Keywords:
disease;
dolorosa dercum;
adiposis dolorosa;
dcfpyl pet ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2022 at "Radiology"
DOI: 10.1148/radiol.211836
Abstract: Background Data regarding 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine 3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) PET in primary staging of prostate cancer (PCa) are limited. Purpose To compare the performance of 18F-DCFPyL PET/CT or PET/MRI (PET) with bone scan and CT with or…
read more here.
Keywords:
pet;
dcfpyl pet;
18f dcfpyl;
conventional imaging ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Radiology"
DOI: 10.1148/radiol.220218
Abstract: Background Prostate-specific membrane antigen (PSMA) PET is standard for newly diagnosed high-risk and biochemically recurrent (BCR) prostate cancer. Although studies suggest high specificity of 2-(3-{1-carboxy-5-[(6-[(18)F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (DCFPyL) for targeting PSMA, false-positive findings have been identified…
read more here.
Keywords:
prostate;
dcfpyl pet;
prostate cancer;
Photo by nci from unsplash
Sign Up to like & get
recommendations!
1
Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.5501
Abstract: 5501Background: Current imaging modalities are inadequate for localizing and characterizing occult disease in men with BCR PCa, particularly in pts with low PSAs (
read more here.
Keywords:
impact psma;
targeted imaging;
18f dcfpyl;
dcfpyl pet ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2022 at "PLOS ONE"
DOI: 10.1371/journal.pone.0277407
Abstract: Background While prostate specific membrane antigen (PSMA) is overexpressed in high-grade prostate cancers, it is also expressed in tumor neovasculature and other malignancies, including hepatocellular carcinoma (HCC). Importantly, no functional imaging for HCC is clinically…
read more here.
Keywords:
pet;
trial;
dcfpyl pet;
18f dcfpyl ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2022 at "Hellenic journal of nuclear medicine"
DOI: 10.1967/s002449912431
Abstract: OBJECTIVE Fluorine-18-2-(3-{1-carboxy-5-[(6-18F-flfluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL), a novel positron emission tomography/computed tomography (PET/CT) radiotracer that binds to the prostate specific membrane antigen (PSMA), is increasingly used for biochemically recurrent prostate cancer diagnostics. However, the 18F-DCFPyL characteristics of…
read more here.
Keywords:
prostate cancer;
dcfpyl;
dcfpyl pet;
18f dcfpyl ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
1
Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1025475
Abstract: Objectives Glutamate carboxypeptidase-II (GCP-II), a zinc metalloenzyme that resides in cell membrane, has been reported as overexpressed in the neovasculature of ovarian cancers. The study objective was to determine whether GCP-II targeted imaging with 18F-DCFPyL…
read more here.
Keywords:
advanced high;
high grade;
pet;
dcfpyl pet ... See more keywords